Natick firm in life sciences partnership
Life sciences firm SBH Sciences of Natick is linking up with a Georgia company in a collaborative venture to research and develop a class of drugs that can treat a variety of diseases, the two firms announced.
SBH and its partner, Galectin Therapeutics of Norcross, Ga., are forming Galectin Sciences, whose goal will be to research and develop small organic molecule inhibitors of what is known as galectin-3, part of a class of proteins made by many cells in the body, according to a statement by the firms.
"Increased levels of galectin proteins have been implicated in a very large number of inflammatory, fibrotic and neoplastic diseases,” said Peter G. Traber, president, CEO and chief medical officer for Galectin Therapeutics. “The discovery and development of orally active galectin inhibitors would be a major step towards expanded treatment approaches for these disorders.”
SBH has provided services for Galectin Therapeutics for more than 10 years, according to SBH President Raphael Nir. He called today’s announcement a “transformational point for SBH Sciences (that) represents the shift in our business model from service provider to biotechnology company.”
WBJ Web Partners
Most Recent
Most Recent
0 Comments